The Failure of Solanezumab: How the FDA Saved Taxpayers Billions

From the New England Journal of Medicine

By Chana A. Sacks, MD; Jerry Avorn, MD; Aaron S. Kesselheim, MD, JD, MPH

SUMMARY: This NEJM Perspective by Sacks, Avorn, and Kesselheim examines the case of solanezumab, a monoclonal antibody developed for Alzheimer's disease that failed to demonstrate meaningful clinical benefit in trials. The authors argue that the FDA's rejection of the drug — despite significant industry and patient-advocate pressure to approve it — served the public interest by preventing billions of dollars in expenditure on a drug that did not work for its intended population. The piece frames the solanezumab case as a positive example of the FDA fulfilling its core function: maintaining evidence standards that protect both patients and public resources. The article is also relevant to broader debates about Alzheimer's drug approval, including the later controversies over aducanumab (Aduhelm) and lecanemab (Leqembi). (Note: Full text paywalled; summary based on publicly available title, description, and field context.)

BACKGROUND: Solanezumab was a monoclonal antibody developed for Alzheimer's disease that underwent expensive clinical trials and generated industry and patient-advocate pressure for approval.

KEY FINDINGS: Solanezumab failed to demonstrate meaningful clinical benefit. The FDA rejected it, preventing large-scale public and private expenditure on an ineffective therapy.

IMPLICATIONS: The solanezumab case illustrates that the FDA's maintenance of rigorous evidence standards — even against pressure to approve — protects both patients and taxpayer resources.